Legal Representation
Attorney
Roman Fayerberg
USPTO Deadlines
Application History
21 events| Date | Code | Type | Description | Documents |
|---|---|---|---|---|
| Jun 6, 2023 | MAB2 | E | ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND | Loading... |
| Jun 5, 2023 | MAB2 | O | ABANDONMENT NOTICE MAILED - FAILURE TO RESPOND | Loading... |
| Jun 5, 2023 | ABN2 | O | ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE | Loading... |
| Oct 17, 2022 | GNFN | O | NOTIFICATION OF FINAL REFUSAL EMAILED | Loading... |
| Oct 17, 2022 | GNFR | O | FINAL REFUSAL E-MAILED | Loading... |
| Oct 17, 2022 | CNFR | R | FINAL REFUSAL WRITTEN | Loading... |
| Apr 13, 2022 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED | Loading... |
| Apr 13, 2022 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | Loading... |
| Apr 12, 2022 | ALIE | A | ASSIGNED TO LIE | Loading... |
| Apr 7, 2022 | ALIE | A | ASSIGNED TO LIE | Loading... |
| Apr 6, 2022 | PARI | I | TEAS VOLUNTARY AMENDMENT RECEIVED | Loading... |
| Oct 9, 2021 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED | Loading... |
| Oct 8, 2021 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | Loading... |
| Oct 8, 2021 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED | Loading... |
| Apr 20, 2021 | GNRN | O | NOTIFICATION OF NON-FINAL ACTION E-MAILED | Loading... |
| Apr 20, 2021 | GNRT | F | NON-FINAL ACTION E-MAILED | Loading... |
| Apr 20, 2021 | CNRT | R | NON-FINAL ACTION WRITTEN | Loading... |
| Mar 24, 2021 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
| Dec 12, 2020 | MDSM | E | NOTICE OF DESIGN SEARCH CODE E-MAILED | Loading... |
| Dec 11, 2020 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | Loading... |
| Oct 27, 2020 | NWAP | I | NEW APPLICATION ENTERED | Loading... |
Detailed Classifications
Class 042
Research and development related to platelets, platelet variants, megakaryocytes, megakaryocytes variants, and products derived from platelets, megakaryocytes or their variants, including, extracellular vesicles or exosomes; Research and development in the field of allogeneic cell therapy, platelet variants, drug delivery and pharmaceutical compositions comprising platelet variants for the treatment of tumors, immune-oncology, hematology, cardiovascular, inflammatory, immune and autoimmune diseases, conditions, or responses, critical care disorders, conditions and injuries, solid organ transplantation, wound healing, neurological disorders, and orthopedics; Biotechnology research; Research in the field of allogeneic cell therapy, platelet variants and pharmaceutical compositions comprising platelet variants; Pharmaceutical research and development; Medical research; Scientific research; Medical and scientific research in the field of allogeneic cell therapy, platelet variants, and pharmaceutical compositions comprising platelet variants for the treatment of tumors, immune-oncology, hematology, cardiovascular, inflammatory, immune and autoimmune diseases, conditions, or responses, critical care disorders, conditions and injuries, solid organ transplantation, wound healing, neurological disorders, and orthopedics; Research and development related to viral vectors and delivery of viral vectors
First Use Anywhere:
0
First Use in Commerce:
0
Additional Information
Design Mark
The mark consists of the word "PLATELETBIO" to the left of a Pegasus design.
Pseudo Mark
PLATELET BIO
Classification
International Classes
042